🇺🇸 FDA
Pipeline program

TAK-861

TAK-861-3003

Phase 3 small_molecule active

Quick answer

TAK-861 for Narcolepsy Type 1 (NT1) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Narcolepsy Type 1 (NT1)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials